21st week of 2012 patent applcation highlights part 40 |
Patent application number | Title | Published |
20120128612 | AZOLE ANTIFUNGAL COMPOSITIONS - The present invention relates generally to antifugal compositions. In an embodiment, the antifungal compositions are effective for application to nails and surrounding skin, and comprise at least one volatile solvent, at least one film forming substance, and at least one pyrimidone derivative of formula I, such as albaconazole. These compositions are capable of treating an infection caused by fungi, such as onychomychosis. | 2012-05-24 |
20120128613 | COMPOSITIONS COMPRISING A SKIN-LIGHTENING RESORCINOL AND A SKIN DARKENING AGENT - The present invention relates to a composition comprising a skin-lightening resorcinol and a skin darkening agent. The composition may be topically applied to the skin, such as to treat signs of aging. | 2012-05-24 |
20120128614 | SOLVENT, SOLUTION, CLEANING COMPOSITION AND METHODS - A cleaning composition can comprise aqueous, nonaqueous liquid, or solid formulations The formulations can contain a surfactant and a solvent The solvent has been shown to have utility in promoting removal, solubilizing or cleaning undesirable soil residues from a number of substrates The solvent materials can be used as a component of an aqueous solution, can be combined in a solid or powdered formulation as an encapsulated solvent or can be combined in a solid or powdered formulation as a solvent absorbed on a solid earner The aqueous formulations can be made in the form of a concentrate The cleaner can be combined with water to form an active cleaning solution that can be applied in a variety of cleaning processes The cleaner can contain additional ingredients including surfactants, builders, sequestrates, bleaches, biocides, to be found in cleaners of general and specific applications Personal care cleaning products are also described. | 2012-05-24 |
20120128615 | HAIR TREATMENT COMPOSITION - Provided is a hair treatment composition capable of imparting good manageability and excellent hair feel to the hair upon finishing permanent wave or hair dye treatment. The hair treatment composition has the following components (A) and (B): (A) a compound represented by the following formula (1): R | 2012-05-24 |
20120128616 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE ELASTOMERIC POLYURETHANE AND AT LEAST ONE CATIONIC POLYMER - Provided is a cosmetic composition comprising, in a cosmetically acceptable medium, at least one film-forming elastomeric, anionic polyurethane, and at least one cationic polymer, as well as a method for the styling of the hair comprising applying this composition to the hair. | 2012-05-24 |
20120128617 | HAIR TREATMENT AGENTS COMPRISING POLYETHER-MODIFIED ORGANIC COMPOUNDS AND HAIR STYLING POLYMERS - Hair treatment agents that, in addition to at least one hair-setting polymer, additionally contain polyether-modified organic compounds having at least three polyether substituents, the polyethers comprising a polyalkylene chain made up of ethylene oxide units or ethylene oxide units and propylene oxide units, having a maximum proportion of 50 wt % propylene oxide units based on weight of the polyoxyalkylene chain. | 2012-05-24 |
20120128618 | COSMETIC CLEANING AGENT HAVING NOVEL MIXTURE OF ACTIVE AGENTS - A cosmetic cleaning and care agent having good foaming properties includes a) at least one mild anionic surfactant and at least one mild amphoteric/dipolar ionic surfactant, wherein the total quantity of mild anionic and mild amphoteric/dipolar ionic surfactant is 3 to 20% by weight, b) 0.005 to 5% by weight of at least one non-ionic cellulose ether, and c) 0.005 to 5% by weight of at least one non-ionic polymer of the formula (I), where R stands for a hydrogen atom or methyl group, and n stands for an average value of 10 to 1200. | 2012-05-24 |
20120128619 | COSMETIC AGENT - A cosmetic agent particularly useful for the styling of keratin fibers such as human hair is disclosed. The cosmetic agent of the present invention contains a unique combination of specific amphoteric polymers with an amphiphilic anionic polymer that imparts optimized properties to the agent without additional active ingredients. Styling agents containing this inventive polymer combination provide a very high degree of hold and moisture resistance to keratinous fibers without compromising flexibility. | 2012-05-24 |
20120128620 | ANIMAL LITTER - An animal litter is provided. The animal litter includes zeolite, a sub-blend comprising organic proteins, amino acids, carbohydrates, surfactants, and oxidizers, and a blend of bacteria that functions as a biological inhibitor, wherein the zeolite and the sub-blend are coupled together by the application of the blend of bacteria. Under the condition that animal waste comes into contact with the animal litter, the zeolite absorbs the liquid in the animal waste, the blend of bacteria destroys parasites and bacteria within the animal waste as well as constructs a physical barrier around the animal waste to inhibit the spread of the parasites and bacteria outside the physical barrier, and the sub-blend controls and neutralizes the odors emanating from the animal waste. | 2012-05-24 |
20120128621 | Long-Wearing Cosmetic Composition - The present invention relates to a cosmetic composition particularly useful for the application of color such as in a foundation, lip gloss, lip stick, mascara, eye shadow, blush, and nail polish, for example. A cosmetic composition according to the present invention includes a film-forming silicone-containing polyurethane having a viscosity from about 130,000 to about 2,500,000 cps, preferable from about 400,000 to about 2,500,000 cps and most preferably from about 750,000 to about 2,500,000. | 2012-05-24 |
20120128622 | MRSA Bactericidal Topical Gel - The present invention is directed to an enhanced wound healing composition, including a gel containing vancomycin, useful for the prevention of the spread of resistant-type bacteria. Preferably, the drug is one or more antibiotic agents in therapeutically effective concentrations to reduce or eliminate MRSA. The composition is based on a gel composition containing one or more gel forming compounds, such as one or more polymers, preservatives, and/or pH stabilizers and buffers, which not only maintains a moist wound environment to enhance wound healing, but also provides an antibiotic agent which has sustained potency and stability. The composition, when placed in contact with a treatment site, delivers the drug to the site. By incorporating the drug into the gel composition that is formulated to enhance wound healing, the treatment of such disease is possible in a manner which promotes wound healing while reducing or eliminating the MRSA microbe. | 2012-05-24 |
20120128623 | SURFACE ANTI-BIOMOLECULE AGENT - This invention discloses a surface anti-biomolecule agent for an artificially or naturally charged substrate. The anti-biomolecule agent comprises a copolymer employing anchoring blocks or domains to binds sites of the substrate via electrostatic attractive force, and employing zwitterionic blocks or domains extended outwardly to reduce the attachment of biomolecules to the substrate. | 2012-05-24 |
20120128624 | Recombinant Human Albumin-Granulocyte Macrophage Colony Stimulating Factor Fusion Protein With Long-Lasting Biological Effects - Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast. | 2012-05-24 |
20120128625 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS - Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells. | 2012-05-24 |
20120128626 | ANTI-IL-6 ANTIBODIES FOR THE TREATMENT OF ANEMIA - The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat anemia (e.g., anemia associated with chemotherapy) including persons on a treatment regimen with a drug or chemotherapy and/or radiation for cancer (e.g., head and neck cancer) that is associated with increased risk of anemia. | 2012-05-24 |
20120128627 | IL-17 HOMOLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF - The present invention is directed to novel polypeptides having sequence identity with IL-17 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders. | 2012-05-24 |
20120128628 | COMBINATION OF A NUCLEOSIDE POLYMERASE INHIBITOR WITH A MACROCYCLIC PROTEASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF HEPATITIS C, LIVER FIBROSIS AND IMPAIRED LIVER FUNCTION (as amended) - Embodiments disclosed in the present application relate to a composition that can include a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. Additional embodiments disclosed relate to methods for treating a disease condition such as a hepatitis C virus infection, liver fibrosis and/or impaired liver function with a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. | 2012-05-24 |
20120128629 | METHOD OF LABELLING INTERFERONS WITH PEG - A method of site specific labelling of an interferon molecule is provided. The method comprises the steps: a) providing a label molecule comprising a PEG moiety having an aldehyde or ketone moiety; b) providing an interferon molecule having a C terminal hydrazide moiety; and c) allowing the aldehyde or ketone moiety of the PEG moiety to react with the C terminal hydrazide of the interferon molecule to form a labelled interferon molecule, which comprises a PEG moiety attached to the C terminus of the interferon molecule via a hydrazone bond. Interferon molecules labelled using such a method are also described. | 2012-05-24 |
20120128630 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE - The present invention concerns a 1-(6 members azo-heterocyclic)-pyrrolin-2-one compound of the following formula I or a salt, solvate, tautomer, isotope, enantiomer, diastereoisomer or racemic mixture thereof: the pharmaceutical composition thereof and their therapeutic use as inhibitors of Hepatitis C NS5B polymerase. | 2012-05-24 |
20120128631 | COMPOSITIONS AND METHODS FOR KINASE-MEDIATED CYTOPROTECTION AND ENHANCED CELLULAR ENGRAFTMENT AND PERSISTENCE - Disclosed are methods of protecting cells, especially non-vascular system, non-hematopoietic cells and tissues, from apoptosis and enhancing their engraftment, survival, and/or persistence by providing enhanced levels of PIM activity for the cell, including PIM-1 activity. Also disclosed are cells that have been engineered to express enhanced levels of PIM kinase, and methods of administering those cells to vertebrates. | 2012-05-24 |
20120128632 | IDENTITY MARKERS - Methods for identifying trichogenic dermal cells, including dermal papilla cells and dermal sheath cells, capable of inducing hair follicle formation when injected into skin are provided. It has been discovered that EGF latrophilin and seven transmembrane domain-containing protein 1 (ELTD1). Transmembrane Protein 108 (TMEM1 08), Hyaluronan and proteoglycan link protein 1 (HAPLN1) are biomarkers that can be used to detect, identify, and distinguish trichogenic dermal cells, i.e., that are able to induce hair follicle formation, from other skin cells. Populations of skin cells enriched with trichogenic dermal cells can be produced by selecting for and enriching for dermal cells that express ELTD1, TMEM1 08, HAPLN1, or a combination thereof. | 2012-05-24 |
20120128633 | USE OF COLLINSELLA AEROFACIENS FOR REDUCING BLOATING - The invention relates to compositions comprising | 2012-05-24 |
20120128634 | USE OF COLLINSELLA AEROFACIENS FOR REDUCING BLOATING - The invention relates to compositions comprising | 2012-05-24 |
20120128635 | METHODS AND COMPOSITIONS FOR TREATING HEMOPHILIA B - Disclosed herein are methods and compositions for insertion of Factor IX (FIX) sequences into the genome of a cell for treating hemophilia B. | 2012-05-24 |
20120128636 | Gingiva Derived Stem Cell And Its Application In Immunodulation And Reconstruction - The present invention relates to gingiva derived messenchymal stem cells (GMSCs). More specifically, the invention provides compositions and methods of using GMSCs to regulate inflammatory response in the setting of normal versus pathological wound healing and to treat inflammatory and/or autoimmune diseases. | 2012-05-24 |
20120128637 | Cellular Seeding and Co-Culture of a Three Dimensional Fibroblast Construct - The present invention provides methods for cellular seeding onto three-dimensional fibroblast constructs, three-dimensional fibroblast constructs seeded with muscle cells, and uses therefore. | 2012-05-24 |
20120128638 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HEART DISEASES - The present invention is related to a pharmaceutical composition comprising cells committed to the generation of heart tissue and at least one pharmaceutically acceptable excipient produced according to internationally recognized standards for pharmaceutical product manufacture, a process for the manufacture of such a pharmaceutical composition and a kit for the administration of said pharmaceutical composition which comprises a container containing said pharmaceutical composition. | 2012-05-24 |
20120128639 | In Vitro Production Of Oligodendrocytes From Human Umbilical Cord Stem Cells - The invention provides a method of producing oligodendrocytes by in vitro differentiation of human multi-potent progenitor cells (MLPCs). The method comprises culturing isolated MLPCs on a first surface in a serum-free defined culture medium; replacing the culture medium with serum-free culture medium supplemented with bFGF, EGF and PDGF-AA for approximately 24 hours; changing the cultured MLPCs into the supplemented serum-free culture medium further supplemented with differentiation factors norepinephrine, forskolin. and K252a; establishing a 3D environment by covering the culture with a second surface opposite and spaced apart from the first surface, so as to contain the MLPCs therebetween; and continuing to culture until a majority of the MLPCs have differentiated into oligodendrocytes. Additionally included is a method of treatment for a subject afflicted by a disease characterized by central or peripheral nervous system demyelination, the method comprising transplanting into the subject oligodendrocytes produced according to the method disclosed. | 2012-05-24 |
20120128640 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS - An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various disorders is provided. | 2012-05-24 |
20120128641 | METHODS AND COMPOSITIONS FOR IMPROVING THE VIABILITY OF CRYOPRESERVED CELLS - The present invention provides polymers and methods for increasing the viability of cryopreserved cells after thawing. Thawing cryopreserved cells in the presence of a polymer such as poloxymer P1 88 or other non-ionic polymers is thought to stabilize the membranes of the cells leading to increased post-thaw viability. Such methods may be used in the processing of cells and tissues for transplantation or for research purposes. Other agents such as antioxidants, vitamins, or osmotic protectants may also be added to cells to improve viability. | 2012-05-24 |
20120128642 | POTENCY MARKERS - Methods for identifying trichogenic dermal cells, including dermal papilla cells and dermal sheath cells, capable of inducing hair follicle formation when injected into skin are provided. Biomarkers have been discovered that can be used to detect, identify, and distinguish trichogenic dermal cells, i.e., that are able to induce hair follicle formation, from non-trichogenic skin cells. Populations of enriched trichogenic dermal cells can be produced by selecting for and enriching for dermal cells that the disclosed biomarkers. These enriched trichogenic dermal can be used for inducing hair follicle formation. | 2012-05-24 |
20120128643 | GENE VECTOR - A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC but not in a differentiated cell. | 2012-05-24 |
20120128644 | Use of Bacteria to Treat and Prevent Respiratory Infections - The invention provides methods for treating respiratory infections by administering compositions comprising one or more isolated, non-pathogenic, hydrogen peroxide-producing bacterial species or strains to the mouth, oropharynx, larynx, nasal cavity, fauces of a subject. | 2012-05-24 |
20120128645 | PROPHYLACTIC, AMELIORATING OR THERAPEUTIC AGENT FOR ORAL DISEASES - To provide a novel lactic acid bacterium strain having a broad antibacterial spectrum against bacteria that cause oral diseases, from which a fermented product having good flavor and being excellent in palatability can be produced, and a prophylactic, ameliorating or therapeutic agent for oral diseases using the same. | 2012-05-24 |
20120128646 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASE - The present invention is related to the development and treatment of autoimmune disease. Autoimmune diseases can result from tissue damage caused by the activation of autoreactive T cells by autoantigens. For example, peptide fragments of naturally occurring proteins (i.e., for example, chromogranin A) may activate autoreactive T cells that result in the destruction of pancreatic β islet cells, possibly by the release of inflammatory cytokines (i.e., for example, interferon-γ). One naturally occurring biologically active chromogranin A peptide fragment, WE14, may comprise a diabetogenic autoantigen. Truncation and extension analysis of WE14 indicates that the stimulating binding register of WE14 occupies only half of the mouse IA | 2012-05-24 |
20120128647 | DELIVERY OF COMPOUNDS WITH REHYDRATED BLOOD CELLS - Fixed-dried blood cells carrying an active agent are described, along with methods of making the same, methods of using the same, and compositions containing the same. The blood cells are preferably blood platelets. | 2012-05-24 |
20120128648 | Novel Biopesticide Compositions And Method For Isolation And Characterization Of Same - The present invention describes the isolation and characterization of the novel biopesticide compositions and/or biopesticide formulations obtained from | 2012-05-24 |
20120128649 | MODIFIED NON-CYTOTOXIC PROTEASES - The present invention relates to a modified polypeptide comprising a non-cytotoxic protease, a translocation domain, a destructive protease cleavage site and a Targeting Moiety that binds to a Binding Site on a nerve cell, wherein after cleavage of the destructive cleavage site the polypeptide has reduced potency. The destructive cleavage site is recognised and cleaved by a protease present at or in an off-site target cell, and, in one embodiment, the polypeptide is a modified clostridial neurotoxin. The present invention also relates to the use of said polypeptides for treating a range of conditions, and to nucleic acids encoding said polypeptides. | 2012-05-24 |
20120128650 | EXTENDED ACTING OXYGEN GENERATING COMPOSITION FOR TREATING MICROBIAL INFECTIONS - A medicament for the treatment or prevention of a microbial infection or an associated condition in a low oxygen environment characterised in that the medicament includes an extended acting oxygen generating system. | 2012-05-24 |
20120128651 | ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) BIOMARKERS - The present invention concerns the use of biomarkers for acute lymphoblastic leukemia (ALL) to prognose or evaluate a patient with ALL who is Ph+. Methods and compositions are provided that concern these ALL biomarkers. In specific embodiments, methods for determining whether an ALL patient should be treated with standard chemotherapy are provided. | 2012-05-24 |
20120128652 | ENDOLYSIN PLYP40 - The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO:1. The present invention further relates to the nucleic acid molecules comprising a nucleotide sequence coding for the polypeptide, vectors comprising the nucleic acid molecules, and host cells for the expression of the polypeptides. In addition, the present invention relates to the use of the polypeptide as a human medical, veterinary medical or diagnostic substance, as an antimicrobial substance in food, in cosmetics, as disinfecting agent or in the environmental field. | 2012-05-24 |
20120128653 | PROCESS FOR MAKING DRY AND STABLE HEMOSTATIC COMPOSITIONS - Described is a process for making a dry and stable hemostatic composition, said process comprising
| 2012-05-24 |
20120128654 | Allantoin Administration for the Treatment of Neurodegenerative Disease and Neurotrauma - Methods for inhibiting the progression of neurodegenerative diseases and treating neurotrauma-induced damage and cerebrovascular disease are provided herein, the methods including the administration of a safe and effective amount of allantoin to a patient in need thereof. Also provided are pharmaceutical compositions including allantoin for the inhibition of the progression of neurodegenerative diseases and for the treatment of neurotrauma-induced damage and cerebrovascular disease. | 2012-05-24 |
20120128655 | INDUCED PLURIPOTENT STEM CELLS - The present invention concerns the delivery of certain reprogramming factor proteins into cells, such as differenti-atedsomatic cells, in order to induce the epi-genetic reprogramming of the cell so it becomes a pluripotent stem cell. The reprogramming factor protein(s) may be Sox2, Klf4, Oct3/4, c-Myc, Lin28, Nanog, or any protein with reprogramming (-enhancing) activity. These proteins may be linked recombinantly or chemically to a cell penetrating peptide that helps facilitate the introduction of these proteins into the target cell and may be preferably expressed in mammalian cells to maintain them in active forms. Accordingly, the present method of inducing pluripotent stem cell (iPS) formation avoids the use of viral or DNA-based expression vectors or the expression of reprogramming factor genes within target cells, which are known to be harmful to the host target cell and cause cancer. | 2012-05-24 |
20120128656 | Vaccine compositions and methods - The present invention relates to pharmaceutical vaccine compositions comprising at least one vaccine antigen together with living immune cells. These immune cells include at least a portion of activated T-cells and act as an adjuvant. Methods for using these pharmaceutical compositions to prevent or treat diseases, such as cancer, infectious diseases and autoimmune disease are also included. | 2012-05-24 |
20120128657 | SYNTHETIC MACROCYCLIC COMPOUNDS AND METHODS FOR TREATING CANCER - Disclosed herein are macrocyclic compounds that are effective to inhibit cell migration. In one embodiment, the compounds have the structure: or any pharmaceutically acceptable salt or solvate thereof, wherein: m is 0 or 1; R | 2012-05-24 |
20120128658 | RAGE G82S-RELATED METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISORDERS - This invention provides methods, compositions and articles of manufacture for inhibiting the onset of and treating inflammatory disorders such as rheumatoid arthritis. The instant invention is based on the blockade of RAGE G82S function. | 2012-05-24 |
20120128659 | AGENTS CAPABLE OF DOWNREGULATING AN MSF-A - DEPENDENT HIF-1ALPHA AND USE THEREOF IN CANCER TREATMENT - Methods and pharmaceutical compositions for the treatment of cancer or acute ischemia are provided. Also provided are methods of identifying agents capable of preventing the formation of or dissociating the MSF-A-HIF-1alpha protein complex, and methods of determining the prognosis of an individual having cancer by identifying the presence or absence of such a protein complex. | 2012-05-24 |
20120128660 | DIAGNOSIS OF RESTENOSIS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION - The present invention relates to compounds, compositions, methods and/or kits for determining and/or predicting and/or diagnosing and/or treating restenosis in a patient. | 2012-05-24 |
20120128661 | POLYNUCLEOTIDE AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER - The present invention relates to polynucleotide and polypeptide sequences which are differentially expressed in cancer cells compared to normal cells. The present invention more particularly relates to the use of these sequences in the diagnosis, prognosis or treatment of cancer and in the detection of cancer cells. | 2012-05-24 |
20120128662 | SUBSTITUTED IMIDAZOQUINOXALINES - The present invention relates to substituted imidazoquinoxaline compounds of general formula (I) as inhibitors of Mps-1 Kinase or TTK, and being active against inflammation and cancer. | 2012-05-24 |
20120128663 | Fc VARIANTS THAT EXTEND ANTIBODY HALF-LIFE - The invention relates generally to compositions and methods for altering the serum half-life in vivo of an antibody. | 2012-05-24 |
20120128664 | GLYCOSYLATED ANTIBODIES - The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof. | 2012-05-24 |
20120128665 | PRESELECTION OF SUBJECTS FOR THERAPEUTIC TREATMENT BASED ON HYPOXIC STATUS - The present invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of hypoxia in cancerous cells in the subject. In one embodiment, the invention provides methods for the preselection of a subject for therapeutic treatment with an agent based on modulated levels of lactate dehydrogenase (LDH) in a cell, e.g., a cancerous cell. The invention also provides methods for treating cancer in a subject by administering an effective amount of an agent to the subject, wherein the subject has been selected based on a modulated level of hypoxia. The invention further provides kits to practice the methods of the invention. | 2012-05-24 |
20120128666 | METHODS OF INCREASING NEURONAL DIFFERENTIATION USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID - Methods are provided for increasing neuronal differentiation of neuronal stem cells using antibodies that bind lysophosphatidic acid (LPA). Particularly preferred antibodies to LPA are monoclonal antibodies, including humanized monoclonal antibodies to LPA. Such antibodies, and derivatives and variants thereof, can be used in increasing neuronal differentiation, and in treatment and/or prevention of injuries, diseases, or conditions associated with insufficient neuronal differentiation and/or with elevated LPA levels in neural tissues. | 2012-05-24 |
20120128667 | PENTAMIDINE COMBINATIONS FOR TREATING CANCER - The present invention relates to the treatment of cancer, e.g., ovarian cancer, breast cancer, pancreatic cancer or colon cancer, with pentamidine and (a) oxaliplatin, (b) gemcitabine, (c) taxol, (d) 5-fluorouracil or (e) CPT 11. | 2012-05-24 |
20120128668 | METHOD OF PROMOTING BONE GROWTH BY AN ANTI-ACTIVIN ANTIBODY - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density. | 2012-05-24 |
20120128669 | MONOVALENT, BIVALENT AND TRIVALENT ANTI HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) NANOBODY CONSTRUCTS FOR THE PREVENTION AND/OR TREATMENT OF RESPIRATORY TRACT INFECTIONS - Amino acid sequences are provided that are directed against and/or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV. The invention also relates to the uses of such amino acid sequences, polypeptides, compounds or constructs for prophylactic and/or therapeutic purposes. | 2012-05-24 |
20120128670 | mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY - Cancer therapy comprising treatment with an mTOR inhibitor, such as a dual mTORC1/mTORC2 inhibitor, such as OSI-027, in combination with an angiogenesis inhibitor. | 2012-05-24 |
20120128671 | NEUTRALIZING MOLECULES TO INFLUENZA VIRUSES - The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza A viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza A virus subtypes, and methods and means for making such antibodies. | 2012-05-24 |
20120128672 | TREATMENT OF CANCER WITH ELEVATED DOSAGES OF SOLUBLE FGFR1 FUSION PROTEINS - The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an extracellular domain of an FGFR1 polypeptide linked to an Fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight. In some embodiments, the patient has a fibroblast growth factor-2 (FGF-2) plasma concentration of at least 6 pg/ml. In some embodiments, the cancer is characterized by a Fibroblast Growth Factor Receptor 2 (FGFR | 2012-05-24 |
20120128673 | MODULATION OF PILR RECEPTORS TO TREAT MICROBIAL INFECTIONS - The present invention provides methods of using agonists and antagonists of PILRα and PILRβ, respectively, to treat | 2012-05-24 |
20120128674 | C3b antibodies and methods for the prevention and treatment of complement-associated disorders - The present invention concerns antibodies to C3b and the prevention and treatment of complement-associated disorder using such antibodies. | 2012-05-24 |
20120128675 | ANTI-FGF19 ANTIBODIES AND METHODS USING SAME - The invention provides anti-FGF19 antibodies, and compositions comprising and methods of using these antibodies, methods using anti-FGF19 antibodies, and methods comprising detection of FGF19 and/or FGFR4. | 2012-05-24 |
20120128676 | MUC1 ANTIBODIES - The present invention pertains to anti-mucin antibodies having improved antigen binding and/or recognition properties as well as a method for improving the antigen binding and/or recognition of an anti-mucin antibody. In particular, the present invention is directed to anti-MUC1 antibodies which are useful in the treatment of cancer. | 2012-05-24 |
20120128677 | PANCREATIC CANCER TARGETS AND USES THEREOF - The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas. | 2012-05-24 |
20120128678 | DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-TMPRSS11E ANTIBODY - [Problem to be Solved] | 2012-05-24 |
20120128679 | Human Antibodies to the Glucagon Receptor - The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels. | 2012-05-24 |
20120128680 | BIOMARKER ANTIBODY AND DIAGNOSIS DEVICE FOR DETECTING CERTAIN AUTOIMMUNE DISEASES - Antibodies which specifically bind to a peptide having the sequence Ala-Ala-Ala-Pro-Ala-Lys-Ala-Ala-Ala-Ala-Pro-Ala-Lys-Thr-Ala-Ala-Ala-Pro-Val (SEQ ID N | 2012-05-24 |
20120128681 | Anti-CK8 Antibodies To Be Used For Treating Colorectal Cancers And Identifying Metastatic And/Or Invasive Phenotypes - The invention relates to antibodies specific to human CK8 and to pharmaceutical compositions for preventing and treating colorectal cancers. The invention also relates to methods for identifying colorectal cancers with an invasive and/or metastatic phenotype including detecting the cleavage of the C-terminal portion of human CK8 on the surface of tumour cells. | 2012-05-24 |
20120128682 | APOLIPOPROTEIN L- I VARIANTS AND THEIR USE - An isolated human Apolipoprotein L-I corresponding to a wild type human Apolipoprotein sequence is modified by a deletion at its C-terminal end. | 2012-05-24 |
20120128683 | AUTISM TREATMENT - A safe and effective treatment to curtail and cure autism spectrum disorders has been described in this invention using insulin, IGF-1, with multiple known adjuvant therapeutic agents, as well as other pharmaceutical, biochemical, nurticeuticals, and biological agents or compounds delivered through the olfactory mucosal region of the nose and external auditory meatus. | 2012-05-24 |
20120128684 | Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use - Disclosed are antibodies that bind to the stem region of influenza hemagglutinin in the neutral pH conformation, hemagglutinin epitopes in the stem region, and methods of making and using both. | 2012-05-24 |
20120128685 | USE OF HIGH-DOSE OXAZAPHOSPHORINE DRUGS IN COMBINATION WITH MONOCLONAL ANTIBODIES FOR TREATING IMMUNE DISORDERS - The present invention relates to methods of treating an autoimmune disorder, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug in combination with immune therapeutics such as, for example, monoclonal antibodies that selectively bind B-cell specific antigens. | 2012-05-24 |
20120128686 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS - The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof. | 2012-05-24 |
20120128687 | NOVEL ANTIBODY FORMULATION - Pharmaceutical liquid formulation of an antibody against human OX40L, a process for the preparation and uses of the formulation. | 2012-05-24 |
20120128688 | ANTI-CXCL13 AND ANTI-CXCR5 ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CANCER AND CANCER CELL MIGRATION - Methods for prevention or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of an antibody to the chemokine CXCL13 and/or the chemokine receptor CXCR5. Another method comprises the step of administering to the subject a therapeutically effective amount of an expression vector that expresses an antibody to the chemokine CXCL13 and/or the chemokine receptor CXCR5. | 2012-05-24 |
20120128689 | ANTI-IL-23 IMMUNOGLOBULINS - The present invention relates to antigen binding proteins to human IL-23, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as Rheumatoid Arthritis (RA). | 2012-05-24 |
20120128690 | METHODS FOR DETERMINING AGENTS THAT TREAT OR PREVENT OBESITY AND/OR OBESITY RELATED DISEASES AND METHODS FOR TREATMENT THEREWITH - The present invention provides methods for determining a putative agent that treats or prevent obesity and/or obesity related diseases comprising contacting cells with the putative agent and measuring the activity and/or level of Maf1 and/or the activity and/or level of KIAA1875. The present invention also provides the agent identified by the methods herein and methods of treating or preventing obesity and/or obesity related diseases in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits or downregulates Maf1 and/or activates or upregulates KIAA1875. | 2012-05-24 |
20120128691 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF - The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease. | 2012-05-24 |
20120128692 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF - The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease. | 2012-05-24 |
20120128693 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF - Cadherin-11 inhibitors and methods for the prevention and treatment of cadherin-11 related diseases are described herein. Cadherin-11 related diseases include cancer and rheumatoid arthritis. | 2012-05-24 |
20120128694 | THERAPEUTIC AGENTS FOR ALZHEIMER'S DISEASE AND CANCER - To provide a therapeutic drug for Alzheimer's disease and/or a cancer. | 2012-05-24 |
20120128695 | TENEURIN C-TERMINAL ASSOCIATED PEPTIDES (TCAP) AND METHODS AND USES THEREOF - The invention provides a novel family of biologically active neuropeptides and the nucleic aid molecules coding for same. The peptides are derived for the C-terminus of the teneurin family peptides (Ten M1-4). These novel peptides, referred to as teneurin C-terminal associated peptides (TCAPs) are active in neuronal communication and are implicated in a number of neuropathologies. They are particularly useful in modulating stress responses and anxiety and in the treatment of cancer. | 2012-05-24 |
20120128696 | METHODS FOR DETECTING AND INHIBITING ANGIOGENESIS - The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue. The invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of α5β1 integrin to a ligand expressed in the tissue; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of α5β1 integrin to a ligand in a tissue associated with the pathological condition. | 2012-05-24 |
20120128697 | NOTCH Inhibition in the Treatment or Prevention of Atherosclerosis - The present invention is directed to methods of treating or preventing atherosclerosis and other cardiovascular diseases by administering agents that inhibit or modulate the NOTCH signaling pathway. In addition, the invention encompasses methods for assaying compounds for their ability to treat atherosclerosis based upon their effects on NOTCH signaling, and for measuring levels of amount, function, or activity of NOTCH pathway components in biological samples. | 2012-05-24 |
20120128698 | DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DEMYELINATING DISEASES - The present invention concerns the diagnosis and treatment of autoimmune demyelinating diseases, such as multiple sclerosis (MS), by means of a CLM-I agonist. | 2012-05-24 |
20120128699 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE - The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These TROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen. | 2012-05-24 |
20120128700 | CONSTRUCTS FOR DELIVERY OF THERAPEUTIC AGENTS TO NEURONAL CELLS - A non-toxic polypeptide, for delivery of a therapeutic agent to a neuronal cell, comprises a binding domain that binds to the neuronal cell, and a translocation domain that translocates the therapeutic agent into the neuronal cell, wherein the translocation domain is not a H | 2012-05-24 |
20120128701 | COMPOSITIONS AND METHODS FOR THE REMOVAL OF BIOFILMS - Methods of breaking down a biofilm or inhibiting, preventing or treating a microbial infection that produces a biofilm are disclosed, which involves administration of a polypeptide that has one or more HMG-box domains to a subject suffering from the infection or having the biofilm. By competing with microbial proteins that bind to DNA scaffold in the biofilm, these polypeptides destabilize the biofilm leading to destruction and removal of the biofilm by the immune system. | 2012-05-24 |
20120128702 | NOVEL BIOMARKERS FOR A PREDICTION OF THE OUTCOME OF AN IMMUNOTHERAPY AGAINST CANCER - The present invention relates to methods for predicting the effect of an immunotherapy against cancer in a patient based on new biomarkers. The present invention furthermore relates to a prognosis regarding the outcome based on said biomarkers. The present invention furthermore relates to panels of biomarkers for use in the above methods. | 2012-05-24 |
20120128703 | Aminopterin Dosage Forms and Methods for Inflammatory Disorders - There is disclosed dosage forms and methods for treating a patient with an inflammatory disorder with a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, that achieve efficacy without concomitant toxicity. Specifically, there is disclosed a method for treating an inflammatory disorder in a patient with uninterrupted doses of aminopterin. | 2012-05-24 |
20120128704 | REPERTOIRE OF ALLO-RESTRICTED PEPTIDE-SPECIFIC T CELL RECEPTOR SEQUENCES AND USE THEREOF - The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. The invention is further directed to a kit-of-parts or composition containing at least three groups of transgenic lymphocytes transformed with vectors coding for TCR against said antigens. Furthermore, the present invention provides a pharmaceutical composition and its use in the treatment of diseases involving malignant cells expressing said tumor-associated antigens. The invention further relates to a nucleic acid molecule coding for a TCR that recognizes the survivin antigen, a TCR encoded thereby and a T cell expressing said TCR. Further, the invention discloses a vector, a cell and a pharmaceutical composition encoding/containing same and their use in the treatment of diseases involving malignant cells expressing survivin. | 2012-05-24 |
20120128705 | C6ORF167 PEPTIDES AND VACCINES CONTAINING THE SAME - Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the C6orf167 gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing peptides derived from C6orf167 or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from C6orf167, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention. | 2012-05-24 |
20120128706 | IMMUNE ADJUVANT COMPRISING ATP - This invention relates to an immunoadjuvant, which has an excellent antibody production enhancing function and is highly safe, and a vaccine composition comprising the immunoadjuvant. More specifically, the present invention relates to an immunoadjuvant comprising ATP or its pharmaceutically acceptable salt, its solvate, or its derivative having a physiological function as an active ingredient, and a vaccine composition comprising the immunoadjuvant. | 2012-05-24 |
20120128707 | STREPTOCOCCUS PNEUMONIAE PROTEINS AND NUCLEIC ACIDS - The invention provides proteins and nucleic acid sequences from | 2012-05-24 |
20120128708 | DIAGNOSTIC MYCOBACTERIUM TUBERCULOSIS TEST - A method of diagnosing | 2012-05-24 |
20120128709 | EXPRESSION OF RECOMBINANT PROTEINS - The invention provides auto-inducible systems for expressing recombinant proteins of interest which take advantage of elements of quorum sensing (QS) systems of certain bacteria. These systems can be used to produce commercial quantities of proteins such as antigens, which can be used to prepare pharmaceutical compositions. | 2012-05-24 |
20120128710 | Enhancement of Pathogen-Specific Memory Th17 Cell Responses - Compositions and methods for enhancing Th1/Th17 cell responses and decreasing Th2 cell responses are disclosed herein. In various embodiments the present invention describes activation of human dendritic cells and enhancement of antigen-specific T cell responses in a Dectin-1-expressing human dendritic cells comprising an anti-Dectin-1-specific antibody or fragment thereof fused with one or more antigens. TLR2 ligands may also be included to enhance the activation and for enhancement of T-cell responses. Further, the invention also includes methods based on the compositions described herein for the treatment of pathogenic infections. | 2012-05-24 |
20120128711 | ANTI-INFLAMMATORY APPROACH TO PREVENTION AND SUPPRESSION OF POST-TRAUMATIC STRESS DISORDER, TRAUMATIC BRAIN INJURY, DEPRESSION AND ASSOCIATED DISEASE STATES - A composition and methods of use are disclosed for prevention and control of inflammation and oxidative stress and various associated medical conditions, including PTSD, chronic depression and traumatic brain injury. A composition providing a phytonutrient and enriched mushrooms having enhanced Vitamin D and ergothioneine are disclosed. The combined use of an enriched mushroom and phytonutrient provide a synergistic effect on cellular longevity and/or cellular rejuvenation of subjects with both a normal and nutritionally deficient diets, improved tolerance to oxidative and/or inflammatory stress, and increased cellular longevity and/or cellular rejuvenation as a result of the neutralization of free radicals and prevention of chronic inflammation. | 2012-05-24 |